Two Sigma Advisers
PGNX

Two Sigma Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Two Sigma Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11,000
Closed -$83K – 2512
2014
Q4 		$83K Buy
+11,000
New +$65.8K ﹤0.01% 2346
2013
Q3 		– Sell
-12,300
Closed -$55K – 2501
2013
Q2 		$55K Buy
+12,300
New +$55.2K ﹤0.01% 2111

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Two Sigma Advisers's PGNX Position: Q1 2015 in Review

Two Sigma Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2015, closing a stake of 11,000 shares — an estimated $83K sold.

Two Sigma Advisers first reported a position in PGNX in Q2 2013 and held it in 2 quarters. The position peaked at $83K in Q4 2014. 107 funds tracked by Wall St. Rank hold PGNX as of Q1 2015.

  • Two Sigma Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Two Sigma Advisers sold 11,000 Progenics Pharmaceuticals Inc shares in Q1 2015, an estimated $83K.
  • Two Sigma Advisers first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Two Sigma Advisers's Progenics Pharmaceuticals Inc position peaked at $83K in Q4 2014.
  • 107 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2015.

Based on Two Sigma Advisers's 13F filing for Q1 2015, filed 15 May 2015.